Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rulonilimab (F520) in Advanced Urothelial Carcinoma
NCT04636515Phase 2Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rulonilimab in urothelial carcinoma (UC), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
rulonilimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04636515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636515.